Navigation Links
Novagali Pharma Presents at AACO the Results of its Pivotal Phase,III Clinical Trial of Vekacia in Children Suffering From Vernal,Keratoconjunctivitis

EVRY, France, June 25, 2007 /PRNewswire/ -- Novagali Pharma, an emerging pharmaceutical company specialized in ophthalmology presents positive results of its pivotal phase III clinical trial positive results from the Phase III clinical study of Vekacia(R) in children suffering from Vernal Keratoconjunctivitis (VKC) at the XIV Afro-Asian Congress of ophthalmology (AACO) held from June 20 to 25 2007 in Marrakech (Morocco).

VKC is a severe form of chronic allergic conjunctivitis characterized by ocular discomfort, pain, itching and intense photophobia, which severely debilitates the patients. This rare disease affects mostly children and young adults living in warm climates worldwide. In this orphan disease, it was shown that both symptoms and signs of disease improved in patients receiving Vekacia(R). Furthermore, the tolerability of Vekacia(R) was excellent.

The study was designed as a clinical phase II/III, multicenter, randomized parallel group, double masked, dose ranging, controlled study divided in two treatment periods: (I) a four-week prospective, randomized, multicenter, double-masked, three parallel-group, vehicle-controlled treatment period; and (II) a three-month prospective, multicenter, double-masked treatment period.

The primary objective of Vekacia(R) phase III study was to assess the efficacy of Vekacia(R) 0.05 % and Vekacia(R) 0.1%, administered four times daily, versus a vehicle after a four-week treatment period for patients with VKC. The secondary objectives were to compare the safety and ocular tolerance (objective and subjective) and the long-term safety after four months.

One hundred and eighteen patients (mean age: 8.8) with active bilateral VKC (acute or chronic) were enrolled in the study at over 21 sites in Europe and Mediterranean countries from May 2006 to October 2006. Most patients were suffering from perennial VKC (90 patients, 76.3%) and were presented
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Novagali Pharma Announces Positive Vekacia Clinical Results From Pivotal Phase III Trial in Vernal Keratoconjunctivitis
2. Sygnis Pharma AG announces date for presentation of clinical results
3. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
7. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
8. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
9. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
10. Array BioPharma to Present at the C.E Unterbeg, Towbin Emerging Growth Conference
11. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
Post Your Comments:
(Date:8/4/2015)... , Aug. 4, 2015  Intec Pharma Ltd. (the ... company focused on developing drugs based on its proprietary ... its initial public offering in the United ... at a price to the public of $6.00 per ... the ordinary shares are being offered by the Company.  ...
(Date:8/4/2015)... NEW YORK , August 4, 2015 /PRNewswire/ ... new research report with market overview, trends, DRO ... analysis, recent developments, competitive scenario and top competitor ... of Abuse Testing Market Development and Demand ... http://photos.prnewswire.com/prnh/20150727/756778 ) , Explore full reports ...
(Date:8/4/2015)... Tenn., Aug. 4, 2015 Second Quarter ... 30.1% over second quarter of 2014 , Net earnings ... million; $51.2 million after adjustments , Diluted net earnings ... Adjusted EBITDA increased 15.2% to $99.4 million ... to a range of 24.0% to 26.0%; Adjusted EBITDA margin ...
Breaking Medicine Technology:Intec Pharma Ltd. Announces Pricing of U.S. Initial Public Offering 2Intec Pharma Ltd. Announces Pricing of U.S. Initial Public Offering 3Global Drug of Abuse (DOA) Testing Market (Size of $2.9 Billion in 2014) to Witness 5% CAGR During 2015 - 2020 2Global Drug of Abuse (DOA) Testing Market (Size of $2.9 Billion in 2014) to Witness 5% CAGR During 2015 - 2020 3Global Drug of Abuse (DOA) Testing Market (Size of $2.9 Billion in 2014) to Witness 5% CAGR During 2015 - 2020 4Global Drug of Abuse (DOA) Testing Market (Size of $2.9 Billion in 2014) to Witness 5% CAGR During 2015 - 2020 5Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 2Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 3Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 4Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 5Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 6Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 7Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 8Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 9Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 10Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 11Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 12Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 13Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 14Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 15Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 16Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 17Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 18Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 19Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 20Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 21Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 22Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 23Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 24Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 25Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 26Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 27Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 28Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 29Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 30
... Conference on Avian,Influenza at France's Pasteur Institute, PARIS, ... of,Novavax Inc.'s pandemic influenza vaccine provided protection,against a ... data presented here today at the Second International,Conference ... show that two 0.6 microgram doses of Novavax's,virus-like ...
... of Rare but Devastating,Condition , LONDON, June 1, ... of Leicester and have today (Friday June 1),announced ... rare but,devastating medical condition that can affect children ... clinicians and scientists from the two,universities have already ...
Cached Medicine Technology:Novavax Pandemic Flu Vaccine Provided Protection Against a Lethal,Challenge of Live Virus, Pre-Clinical Data Show 2Novavax Pandemic Flu Vaccine Provided Protection Against a Lethal,Challenge of Live Virus, Pre-Clinical Data Show 3Novavax Pandemic Flu Vaccine Provided Protection Against a Lethal,Challenge of Live Virus, Pre-Clinical Data Show 4World First Medical Treatment Announced by Researchers at Queen,Mary University London and University of Leicester 2World First Medical Treatment Announced by Researchers at Queen,Mary University London and University of Leicester 3World First Medical Treatment Announced by Researchers at Queen,Mary University London and University of Leicester 4World First Medical Treatment Announced by Researchers at Queen,Mary University London and University of Leicester 5
(Date:8/5/2015)... ... August 05, 2015 , ... What language does a body ... unique “dictionary” of American idioms and other expressions that contain the name of a ... entertaining. This book contains about 2,000 such idioms, words, and expressions, for example, “back ...
(Date:8/5/2015)... ... August 05, 2015 , ... " Wildflower Seed & Tool Company ” ... look small, medium, and large businesses making an impact in their industry. Susan Bridges, ... with viewers how their gardening tools are specifically designed for women. , With overweight ...
(Date:8/5/2015)... ... August 05, 2015 , ... ... funding, as well as awareness, education and support in order to reduce the ... Foundation proudly announces this year it has awarded the most funding in ...
(Date:8/4/2015)... (PRWEB) , ... August 05, 2015 , ... ... a Texas-based corporation, Crestwood Midstream, to store liquid propane gas (LPG) next to ... powerful healthcare workers union, unanimously passed a resolution that strongly opposes that permit. ...
(Date:8/4/2015)... , ... August 04, 2015 , ... NOVA Pride ... of whom or how they love or identify, to join them in paving “The ... Bull Run Special Events Center on Saturday, October 3, 2015, from 12-9pm. In order ...
Breaking Medicine News(10 mins):Health News:Harvard Medical Professor Dr. Per-Olof Hasselgren Pens Unique Book Using Body Part Idioms 2Health News:Wildflower Seed & Tool Company Design Gardening Tools Specifically for Women 2Health News:Brain Aneurysm Foundation Awards Largest Amount of Research Funding at 9th Annual Brain Aneurysm Foundation Research Grant Awards Symposium Sept 10th in Houston, Texas 2Health News:Brain Aneurysm Foundation Awards Largest Amount of Research Funding at 9th Annual Brain Aneurysm Foundation Research Grant Awards Symposium Sept 10th in Houston, Texas 3Health News:Brain Aneurysm Foundation Awards Largest Amount of Research Funding at 9th Annual Brain Aneurysm Foundation Research Grant Awards Symposium Sept 10th in Houston, Texas 4Health News:Opposition Mounting to Permit Liquid Propane Gas Storage Next to New York’s Seneca Lake 2Health News:Opposition Mounting to Permit Liquid Propane Gas Storage Next to New York’s Seneca Lake 3Health News:NOVA Pride Announces Theme for the 2015 Northern Virginia Pride Festival 2Health News:NOVA Pride Announces Theme for the 2015 Northern Virginia Pride Festival 3Health News:NOVA Pride Announces Theme for the 2015 Northern Virginia Pride Festival 4
... medical condition, has been and remains under-identified. While it ... people who are at high risk for CKD are ... risk for potentially undiagnosed CKD, a team of public ... and the University of North Carolina (UNC) at Chapel ...
... carry a pronounced risk of suffering weak bones due ... Therefore, physicians need to be vigilant to spot bone ... the report the mix of sedentary behaviors and side ... in suppression of bone growth and mineralization. This makes ...
... turn with the involvement of social services in the case of ... above three times the average for his age. ,The ... does not undergo a sea change. He holds a record of ... ,Connor’s mother and grandmother are expected to attend a ...
... day for 10 years, a seemingly heart-healthy 53-year-old woman ... or family history of hypertension or hyperthyroidism. She did ... any abnormalities of the heart as best doctors and ... palpitations and dizziness nearly to the point of fainting. ...
... the most common treatments for prostate cancer - may increase ... age 65, according to a new study. ,The ... registry of men with prostate cancer. Although the findings need ... that oncologists should weigh the benefits of androgen deprivation therapy, ...
... with a drug used previously in the treatment of ... rats// to human subjects. ,The researchers ... administered daily to the rats which were bred to ... improvement in learning abilities. ,Down's syndrome is ...
Cached Medicine News:Health News:Simple Model to Predict Chronic Kidney Disease 2Health News:Simple Model to Predict Chronic Kidney Disease 3Health News:Bone Fragility, a Risk for Children With Cancer 2Health News:Grossly Overweight Boy Likely to Be Sent into Care 2Health News:Irregular Heartbeat Linked to Genetic Mutation 2Health News:Prostate Cancer Therapy may Increase Risk of Death in Older Patients 2Health News:Discredited Drug may Be Used to Aid Mental Development in Down’s Syndrome Patient 2
... sample processing consists of a clear glass ... a chemical-resistant polypropylene lid, and a set ... The manifold is designed for consistent processing ... simultaneously. Loading, washing, and elution steps can ...
For processing spin columns on QIAvac 24 or QIAvac 6S;...
For processing mini spin columns on QIAvac 24;...
DNA/RNA preparation in 96-well format...
Medicine Products: